NRSN
NeuroSense Therapeutics Ltd (NRSN)
Healthcare • NASDAQ • $0.76-1.02%
- Symbol
- NRSN
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.76
- Daily Change
- -1.02%
- Market Cap
- $29.05M
- Trailing P/E
- N/A
- Forward P/E
- -0.98
- 52W High
- $2.35
- 52W Low
- $0.63
- Analyst Target
- $6.50
- Dividend Yield
- N/A
- Beta
- 1.54
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is head…
Company websiteResearch NRSN on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.